Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.
Very encouraging data from Mologic anti flow LFT - hoping its a nice xmas present and thats CKs target - in line with ramp up of capacity.
No RNS expected but expect SP to suitably march towards 200 imv - we don't need anyone else to tell us where the inflexion points are.
The technology works - tick
Engaged with UK gov - tick
Engaged with US - probably
Regulatory approvals - 'just a process' so anticipated approval
Manufacturing capacity - tick - getting ramped up in UK and overseas but won't be enough
Competition - no problem - not enough tests will be produced globally (but affirmers are cheap and robust)
Distribution - in place
Timescales - pending validation but 2nd wave has highlighted this is endemic and not going away anytime soon
Friday afternoon shone a light on testing in general - plenty of references to saliva based pregnancy test with results in minutes and focus on targeting asymptomatic cases......and the best in class will be.....
The UK have given stamp of approval with initial order so that adds value in itself.
Ciga are already promoting overseas with significant interest.
Expecting some vertical movement tomorrow with plenty of news flow in Oct as mentioned on Monday
Triple digit rise anyone?
Its been a roller coaster watching this over the last couple of months.
My observation has been
May - lots of news flow building up to the LFT to be delivered in 'the summer' - AS has always said they will work as hard as they can and mentioned mid summer was possible in a presentation. Add to that the Medusa news and Neutralising therapy saw a roadmap to various inflexion points.
June - as timescales were scrutinised as well as previous funding commentary and major retail interest the waiting game and the impatience has led to volatility
However, the underlying story hasn't changed and now we wait for the Adeptrix deals, the optmisation (knowing what min approval benchmark is needed) and manufacturing deals as this has always been a challenge of major global scale up.
The timing is still valid more than ever as the risk of more spikes is still present. Knowing that UK/US governments are aware also a big tick in the box around a way out (perhaps the US govt wanted this out asap leading to the mild laughter from AS when asked about if US were aware)
But now looks like the timescales and roadmap has been reset we make steady increases now towards delivery with resulting increases in the price.
Just my view fwiw
because spbhoy he said on 6/5 and 11/5 effectively the same thing and was expecting a more robust date for final product (not approvals) in a few weeks from then.
I remain a patient holder - just comparing the timescales quoted.
Timeframes originally were a few weeks from 11/5 and early June in a recent update. Think we are inside those ...just. Would expect some update this week.
RNS says following encourage from retail and institutional. Well probably not retail ...but US investor could have come with an offer too good not to take. This may not have been on the table 11/5.
Strong near term news flow.
1. Adeptrix BAMs test
2. Cytiva and other distributors plus scale up in house facilities to mass produce.
3. MedUsA
4. Beef up regulatory division (for approvals ?)
5. AvA6000 CTA filing Q3 (see 4)
6. Strategic US investor.
Multiple value inflexion points.
A developed test rather than developing.
Exciting no?
GLA